Aliases & Classifications for Vaccinia

Aliases & Descriptions for Vaccinia:

Name: Vaccinia 12 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 42 D014615
SNOMED-CT 64 111852003
UMLS 69 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results_in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted_by contact with the vaccination site before it has healed, or transmitted_by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to sarcoma and cowpox, and has symptoms including rash, fever and body aches. An important gene associated with Vaccinia is VRK1 (Vaccinia Related Kinase 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and breast.

Wikipedia : 71 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Related Disease Score Top Affiliating Genes
1 sarcoma 29.7 CSF2 IL2
2 cowpox 11.2
3 smallpox 10.5
4 hiv-1 10.2
5 monkeypox 10.2
6 influenza 10.1
7 rheumatoid lung disease 10.1 EIF2AK2 EIF2S1 IRF3 IRF7
8 viral infectious disease 10.1 CEACAM5 IL2
9 exophthalmos 10.0 EIF2AK2 ERVW-1 IL2 IRF3 IRF7
10 encephalitis 10.0
11 melanoma 9.9
12 breast cancer 9.9
13 dermatitis 9.9
14 hepatitis 9.9
15 atopic dermatitis 9.9
16 prostate cancer 9.8
17 prostatitis 9.8
18 pancreatitis 9.8
19 venezuelan equine encephalitis 9.8
20 hepatocellular carcinoma 9.8
21 pancreatic cancer 9.8
22 mucositis 9.8
23 hepatitis c 9.8
24 stomatitis 9.8
25 glioma 9.8
26 parainfluenza virus type 3 9.8
27 malaria 9.7
28 lung cancer 9.7
29 hepatitis c virus 9.7
30 tuberculosis 9.7
31 lassa fever 9.7
32 endotheliitis 9.7
33 colorectal cancer 9.6
34 keratitis 9.6
35 multiple myeloma 9.6
36 arthritis 9.6
37 tick-borne encephalitis 9.6
38 variola major 9.6
39 fibroma 9.6
40 louping ill 9.6
41 rabies 9.6
42 lymphocytic choriomeningitis 9.6
43 ovarian cancer 9.6
44 papilloma 9.6
45 folliculitis 9.6
46 avian influenza 9.6
47 peritonitis 9.6
48 molluscum contagiosum 9.6
49 yellow fever 9.6
50 allergic encephalomyelitis 9.6

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • rash
  • fever
  • body aches

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
2 Antibodies Phase 4,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 2,Phase 1
4 Immunoglobulins Phase 4,Phase 2,Phase 1
5 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
6 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
7
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
9
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 84093 441203 2767
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1 33069-62-4 36314
11
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 446556 60843
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
15
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
16
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2 98-92-0 936
17
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 54575, 6560146 143
18 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 2, Phase 3,Phase 1
20 Analgesics Phase 3,Phase 2,Phase 1
21 Anticonvulsants Phase 3
22 Neurotropin Phase 3
23 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
24 Iron-Dextran Complex Phase 3,Phase 2
25 Krestin Phase 3,Phase 2,Phase 1
26 Micronutrients Phase 3,Phase 2
27 Nicotinic Acids Phase 3,Phase 2
28 Protein Kinase Inhibitors Phase 3,Phase 2
29 Trace Elements Phase 3,Phase 2
30 Vitamin B Complex Phase 3,Phase 2
31 Vitamins Phase 3,Phase 2
32 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1
33 Antimitotic Agents Phase 2, Phase 3,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
35 Antiviral Agents Phase 2, Phase 3,Phase 1
36 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2
38 Antimetabolites Phase 2, Phase 3,Phase 1
39 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
40 Angiogenesis Modulating Agents Phase 2, Phase 3
41
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
42 Folic Acid Antagonists Phase 2, Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
44 Folate Nutraceutical Phase 3,Phase 2
45 Vitamin B3 Nutraceutical Phase 3,Phase 2
46 Vitamin B9 Nutraceutical Phase 3,Phase 2
47
Metronidazole Approved Phase 2,Phase 1 443-48-1 4173
48
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
49
Goserelin Approved Phase 2 65807-02-5 47725 5311128
50
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 230)
id Name Status NCT ID Phase
1 Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) Completed NCT00928577 Phase 4
2 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
5 VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection Enrolling by invitation NCT01374984 Phase 4
6 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
7 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3
8 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3
9 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
10 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
11 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
12 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3
13 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
14 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
15 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
16 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
17 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3
18 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
19 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
20 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2
21 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
22 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
23 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
24 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
25 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
26 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2
27 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2
28 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
29 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
30 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
31 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2
32 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
33 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
34 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2
35 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
36 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2
37 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
38 A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Completed NCT00998543 Phase 2
39 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
40 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
41 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
42 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
43 Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
44 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
45 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
46 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
47 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2
48 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2
49 Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Completed NCT00052351 Phase 2
50 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

MalaCards organs/tissues related to Vaccinia:

39
T Cells, Skin, Breast, Monocytes, Prostate, Nk Cells, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

18
Skin

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 1032)
id Title Authors Year
1
Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. ( 28079473 )
2017
2
Preparation of Cell Cultures and Vaccinia Virus Stocks. ( 28060410 )
2017
3
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. ( 28057259 )
2017
4
Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. ( 28046039 )
2017
5
Concomitant helminth infection downmodulates the Vaccinia virus-specific immune response and potentiates virus-associated pathology. ( 28003150 )
2017
6
Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus. ( 28081672 )
2017
7
Generation of Recombinant Vaccinia Viruses. ( 28060405 )
2017
8
Cutaneous Deficiency of Filaggrin and STAT3 Exacerbates Vaccinia Disease In Vivo. ( 28081250 )
2017
9
Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. ( 27544585 )
2016
10
Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions. ( 27466413 )
2016
11
Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress, autophagy and Wnt pathways. ( 27441866 )
2016
12
Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. ( 26985679 )
2016
13
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors. ( 27213433 )
2016
14
Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. ( 27552933 )
2016
15
Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus. ( 26458834 )
2016
16
The vaccinia virus K1 ankyrin repeat protein inhibits NF-kB activation by preventing RelA acetylation. ( 27503790 )
2016
17
CD69 deficiency enhances the host response to Vaccinia virus infection through altered NK cell homeostasis. ( 27147744 )
2016
18
Single-particle characterization of oncolytic vaccinia virus by flow virometry. ( 27614781 )
2016
19
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. ( 27466414 )
2016
20
Live-Cell Imaging of Vaccinia Virus Recombination. ( 27525721 )
2016
21
Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. ( 26939903 )
2016
22
Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma. ( 27319807 )
2016
23
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. ( 27626058 )
2016
24
Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans. ( 27973399 )
2016
25
Both CD8+ and CD4+ T-Cells Contribute to Corneal Clouding and Viral Clearance Following Vaccinia Virus Infection in C57BL/6 Mice. ( 27170749 )
2016
26
Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy. ( 27119120 )
2016
27
Vaccinia virus uses retromer-independent cellular retrograde transport pathways to facilitate the wrapping of intracellular mature virions during viral morphogenesis. ( 27581988 )
2016
28
NPF motifs in the vaccinia virus protein A36 recruit intersectin-1 to promote Cdc42:N-WASP-mediated viral release from infected cells. ( 27670116 )
2016
29
Vaccinia Virus Immunomodulator A46: A Lipid and Protein-Binding Scaffold for Sequestering Host TIR-Domain Proteins. ( 27973613 )
2016
30
Emergence of a viral RNA polymerase variant during gene copy number amplification promotes rapid evolution of vaccinia virus. ( 27928012 )
2016
31
Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells. ( 27993141 )
2016
32
Sensitization with vaccinia virus encoding H5N1 hemagglutinin restores immune potential against H5N1 influenza virus. ( 27892498 )
2016
33
Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection. ( 27958202 )
2016
34
Highly immunogenic variant of attenuated vaccinia virus. ( 27025484 )
2016
35
Nucleoside Triphosphate Phosphohydrolase I (NPH I) Functions as a 5' to 3' Translocase in Transcription Termination of Vaccinia Early Genes. ( 27189950 )
2016
36
Natural Vaccinia Virus Infection: Diagnosis, Isolation, and Characterization. ( 27517335 )
2016
37
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. ( 27092831 )
2016
38
Complete Genome Sequence of Vaccinia Virus Strain L-IVP. ( 27174282 )
2016
39
The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. ( 27639281 )
2016
40
The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose. ( 26937025 )
2016
41
Enhancing expression of functional human sodium iodide symporter and somatostatin receptor in recombinant oncolytic vaccinia virus for in vivo imaging of tumors. ( 27635026 )
2016
42
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. ( 27006959 )
2016
43
Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release. ( 27502570 )
2016
44
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. ( 26918725 )
2016
45
Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs During Vaccinia Virus-induced Host Shutoff. ( 28003488 )
2016
46
Structural analysis of point mutations at the Vaccinia virus A20/D4 interface. ( 27599859 )
2016
47
Vaccinia vaccine-based immunotherapy arrests and reverses established pulmonary fibrosis. ( 27158671 )
2016
48
An improved high pressure freezing and freeze substitution method to preserve the labile vaccinia virus nucleocapsid. ( 27155322 )
2016
49
Erratum: Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. ( 26949713 )
2016
50
Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. ( 27026359 )
2016

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

GO Terms for Vaccinia

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.7 CD80 CSF2 IRF3
2 response to virus GO:0009615 9.69 BANF1 EIF2AK2 IRF7
3 protein autophosphorylation GO:0046777 9.56 EIF2AK2 EIF2S1 VRK1 VRK2
4 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 DUSP1 DUSP3 VRK3
5 regulation of type I interferon production GO:0032479 9.49 IRF3 IRF7
6 negative regulation of MAPK cascade GO:0043409 9.48 DUSP1 DUSP3
7 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.46 CSF2 IL2
8 positive regulation of interferon-alpha production GO:0032727 9.43 IRF3 IRF7
9 mitotic nuclear envelope reassembly GO:0007084 9.4 BANF1 VRK1
10 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.37 IRF3 IRF7
11 type I interferon biosynthetic process GO:0045351 9.16 IRF3 IRF7
12 viral process GO:0016032 9.1 BANF1 CD80 EIF2AK2 IRF3 IRF7 VRK2
13 MDA-5 signaling pathway GO:0039530 8.96 IRF3 IRF7

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulatory region DNA binding GO:0000975 8.62 IRF3 IRF7

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....